Welcome to HitGen


Get up to date with the latest HitGen articles and join us in the events

  1. News
  2. Press Release

Press Release

  • 24 April 2024
    Infographic | HitGen FY2023&2024Q1 Report
    Infographic | HitGen FY2023&2024Q1 Report
  • 08 April 2024
    Vernalis announces a drug discovery collaboration with C4X Discovery in inflammatory disease
    Vernalis (R&D) Limited (“Vernalis”), a wholly owned subsidiary of HitGen Inc., and C4X Discovery (“C4XD”) are pleased to announce a collaboration to identify modulators of an undisclosed high-value target involved in inflammatory disease.
  • 26 March 2024
    HitGen Partners with LabCentral / BioLabs / MBC BioLabs to Accelerate Biotechnology Discovery
    [San Francisco, CA – March 25, 2024] – LabCentral, a launchpad for high-potential life science and biotech start-ups, BioLabs, an international membership-based network of shared lab and office facilities, and MBC BioLabs, premier providers of co-working laboratory space, announced a partnership with HitGen, a global leader in the design, synthesis, and screening of DNA-encoded chemical libraries (DELs).
  • 21 February 2024
    Hox Therapeutics and Vernalis announce a drug discovery collaboration in oncology
    Hox Therapeutics Ltd (“Hox”) a private biotechnology company developing highly targeted cancer therapies and Vernalis (R&D) Ltd (“Vernalis”), a fully owned subsidiary of HitGen Inc., are pleased to announce a collaboration to identify inhibitors against an undisclosed oncology target.
  • 13 November 2023
    Get ready for the end-of-year sale! Discover the future of drug discovery with OpenDEL™ and save 20% off!
  • 27 October 2023
    Infographic | HitGen FY2023 Q3 Report
  • 19 October 2023
    Venture forces invest millions in new type of treatment for particularly aggressive form of cancer
    A syndicate consisting of the Lundbeck Foundation BioCapital, EIR Ventures, EIFO and UCPH Ventures has just made an investment in the Danish biotech company Dania Therapeutics (Dania Tx).
  • 28 September 2023
    SGC and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery
    CHENGDU, China, September 28, 2023 – Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a partnership with The Structural Genomics Consortium ("SGC"), a public-private partnership that supports the discovery of new medicines through open-access research. HitGen will utilize its DNA-encoded library (DEL) technology platform, specifically OpenDEL™, to screen under-represented targets chosen by SGC.
  • 26 September 2023
    Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology
    CASTRES, France and CAMBRIDGE, England, Sept. 25, 2023 – Pierre Fabre Laboratories and Vernalis (R&D) Ltd ("Vernalis"), a fully owned subsidiary of HitGen Inc., are pleased to announce a long-term partnership to identify pre-clinical candidates against multiple oncology targets.
  • 22 August 2023
    Infographic | HitGen FY2023 Half-Year Report

Thanks for reading!

For more details on how we can advance your innovative drug discovery projects
By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information